Business Wire

BOEHRINGER-INGELHEIM

21.9.2021 14:02:26 CEST | Business Wire | Press release

Share
Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches

Boehringer Ingelheim today announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology research to develop the next generation of precision medicines designed to revolutionize cancer treatments. The acquisition will allow Boehringer Ingelheim to access Abexxa’s expertise in targeting cancer-specific proteins that are located inside the cell, rather than those expressed on the cell membrane. This enlarges the pool of potential cancer antigen targets. In particular, Abexxa’s technology could lead to the development of cancer immunotherapies that are effective in a broader range of patients and cancer types.

“The acquisition of Abexxa bolsters our commitment to tumor-antigen discovery and new ways of targeting intracellular antigens. Their cutting-edge know-how and technologies for antigen discovery and novel antibody generation strongly complement the current approaches we have been applying successfully to enable immune-targeting of cancer cells,” said Clive R. Wood, Ph.D., corporate senior vice president and global head of discovery research, Boehringer Ingelheim. “By expanding our portfolio of antibodies binding novel intracellular tumor antigens, we are striving to develop unique and broadly applicable new immunotherapeutic approaches for cancer patients,” added Wood.

Abexxa’s innovative platform unlocks the ability to target intracellular antigens of cancer cells by recognizing their presentation on the cell surface by MHC class 1 molecules. While the Abexxa platform addresses the more common HLA-A2 peptide presentation, the company has developed specific expertise in the nonclassical MHC class 1 molecule HLA-E, which has the potential to impact a broader set of cancer patients’ antigens. More specifically, Abexxa has developed a first-in-class T-cell receptor (TCR)-like antibody that can be used to disrupt the NKG2A:HLA-E immune checkpoint axis in oncology. Abexxa molecules are also being formulated to recruit immune cells targeting HLA-E peptide complexes on tumors.

In 2016, Boehringer Ingelheim’s Venture Fund, the arm of the company that invests in ground-breaking therapeutic and digital health approaches, awarded Abexxa initial investment funding. Later that year, Abexxa won Boehringer Ingelheim’s Innovation Prize, which facilitates business growth and rewards new companies for their dedication to innovation. The prize allowed Abexxa to expand operations into a shared lab space in Cambridge, Massachusetts, to continue its research. Boehringer Ingelheim’s investment in Abexxa demonstrates how the company is seeking to foster innovation across leading biotech communities, including the Dallas-Fort Worth, Texas, area.

“The investment by Boehringer Ingelheim’s Venture Fund in 2016 was a defining moment for Abexxa,” said Debra Wawro Weidanz, co-founder and CEO of Abexxa. “The acquisition by Boehringer Ingelheim allows our team to access the company’s expertise and capabilities in immuno-oncology and antibody development and to have the opportunity to translate Abexxa technology into a clinical asset,” said Jon Weidanz, Ph.D., co-founder and CSO of Abexxa.

This transaction is the latest in a series of strategic acquisitions and collaborations that reinforce Boehringer Ingelheim’s overall oncology strategy, bringing together cancer immunology and cancer cell directed therapies to fight cancer. This strategy has further strengthened Boehringer Ingelheim’s position in oncology through the development of leading assets and robust capabilities in cancer vaccines, oncolytic viruses, T-cell engagers, antibody drug conjugates (ADCs) and myeloid and stromal cell modulators. By combining its world-class in-house research and development with that of highly innovative biotechnology companies like Abexxa, Boehringer Ingelheim is developing innovative cancer immunology therapies and accelerating the delivery of the next generation of cancer treatments.

Learn more about Boehringer Ingelheim’s innovation in oncology here .

The total transaction includes an upfront payment, milestones and other consideration payments. Abexxa will continue to operate in the Arlington, Texas, area as a Boehringer Ingelheim family company, collaborating extensively with the colleagues at Boehringer Ingelheim’s U.S. research site in Ridgefield, Connecticut.

Please click on the following link for ‘Notes to Editors’:

http://www.boehringer-ingelheim.com/press-release/acquisition-expands-research-cancer-immunology

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Gatik Raises $200 Million; Series D Led by QIA and KDT as Demand for Driverless Commercial Freight Accelerates25.8.2026 15:00:00 CEST | Press release

Gatik, the leader in autonomous trucking, today announced $200 million in financing as demand accelerates for driverless commercial freight across Fortune 50 retail, grocery and CPG supply chains. The Series D round was led by Qatar Investment Authority (QIA) and Koch Disruptive Technologies (KDT), with participation from Millennium Management, ARK Invest, Intact Private Capital and others. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825490075/en/ Gatik Announces Series D round Gatik has built one of the most commercially advanced businesses in autonomous freight, with more than $600 million in contracted revenue, 85,000 fully driverless orders completed, and 99% on-time delivery across its operations. Its trucks move goods across high-frequency regional networks between distribution centers and stores, giving customers a reliable way to add capacity, improve service levels and keep products moving. “This round, led by

Safe Software Opens Registration for the Peak of Data and AI 2027 With More Accessible Access Packages25.8.2026 15:00:00 CEST | Press release

Free passes for public sector professionals, new one-day options, and lower pricing across every pass type open the London conference up to a wider audience. Safe Software (Safe), creator of FME, the only All-Data, Any-AI enterprise integration platform, has announced that registration is open for the Peak of Data and AI 2027, its global conference for data and AI professionals, taking place March 9 to 11, 2027 at the QEII Centre in London, UK. The news builds on Safe's announcement in March 2026 that London would host the biennial conference, which has previously been held in Vancouver, Canada, Bonn, Germany and Seattle, Washington, and draws attendees from North America, Europe, Asia-Pacific, and beyond. Alongside opening registration, Safe has introduced a revised set of access packages designed to bring a broader range of professionals to the event: Free passes for public sector and government professionals, from any country One-day passes, for attendees who are unable to join for

SLB Selected as Strategic Reservoir Partner for the Havstjerne Carbon Storage Project25.8.2026 14:46:00 CEST | Press release

Integrated engineering work will support development of the large-scale carbon storage project ahead of a final investment decision Global energy technology company SLB (NYSE: SLB) today announced it has been selected as strategic reservoir partner for the Havstjerne carbon storage project in the Norwegian North Sea, providing technology and engineering services for the concept and front-end engineering and design (FEED) phases. The Havstjerne project is a large-scale offshore carbon storage development in Norway intended to serve industrial emitters across Europe, operated by Harbour Energy (LSE: HBR) in consortium with Stella Maris CCS, a Yinson Production company. SLB will coordinate an integrated project scope that connects analysis of the underground storage reservoir with injection well design, subsea infrastructure and plans for monitoring stored CO2 as the Havstjerne partnership develops the project’s technical, cost and schedule basis ahead of a final investment decision. The

Moody’s Brings Its Decision-Grade Intelligence to Gemini Enterprise for Financial Services25.8.2026 14:05:00 CEST | Press release

Integration through Moody’s Credit MCP server brings trusted credit ratings, research, and entity intelligence into Google Cloud’s new industry-specific AI solution for financial services Moody’s Corporation (NYSE: MCO) today announced that its connected intelligence is now available in Google Cloud’s Gemini Enterprise for Financial Services through the Moody’s Credit Model Context Protocol (MCP) server. As a launch partner for Google Cloud’s Gemini Enterprise for Financial Services, Moody’s gives financial professionals working in the platform direct access to credit ratings and research from Moody’s Ratings, along with Moody’s curated intelligence on companies, entities, and risk. “Delivering decision-grade intelligence wherever financial professionals work is how we help our customers stay ahead as agentic AI reshapes financial workflows,” said Ana Meauta, Managing Director, Channel Sales Partnerships at Moody’s. “With Gemini Enterprise for Financial Services, our customers can acce

Born in Riyadh. Sold Out in Paris. stc and EWC a Winning Partnership.25.8.2026 13:02:00 CEST | Press release

stc group was the Founding and Elite Partner of the Esports World Cup for the third consecutive year. EWC 2026, the largest edition of the tournament to date, brought together more than 2,000 players and 200 clubs from over 100 countries, competing across 25 tournaments and 24 game titles. stc group, a leading digital enabler, concluded its third consecutive year as a Founding and Elite Partner of the Esports World Cup (EWC), supporting the tournament as it staged its first edition outside Saudi Arabia in Paris. The largest EWC to date brought together more than 2,000 professional players and 200 clubs from over 100 countries, competing across 25 tournaments and 24 game titles for a prize pool exceeding $75 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825372468/en/ Fans hold up the stc/EWC banner during the Esports World Cup 2026 grand final at the Accor Arena in Paris (Photo: AETOSWire) The move to Paris marke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye